Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective-Reference-Cited by-同舟云学术

Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective

Published:2023-05-20 Issue:4 Volume:7 Page:605-615
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Wahono Cesarius Singgih^ORCID,Hamijoyo Laniyati^ORCID,Hendrawan Yuriawati,Rakinaturia Liyana,Mittal Neha,Khanna Prabal,Jain Minal,Isbagio Harry

Funder

Novartis Indonesia

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00401-6.pdf

Reference30 articles.

1. Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53:650–7.

2. Indonesia PR. Diagnosis dan pengelolaan spondiloartritis. Perhimpunan Reumatologi Indonesia; 2021 [Internet] https://reumatologi.or.id/rekomendasi-diagnosis-dan-pengelolaan-spondiloartritis-2021/. Accessed 10 July 2021.

3. Kim D, Kim H, Cho S, Park MC. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective. Int J Rheum Dis. 2019;22:1630–7.

4. Maksymowych WP, Strand V, Nash P, et al. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol. 2018;5:216–23.

5. Maksymowych WP, Choy E, Yazici Y, Walsh JA, Thom H, Kalyvas C, Fox T, Gandhi K, Jugl S. Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). [Internet] https://acrabstracts.org/abstract/comparative-effectiveness-of-secukinumab-and-golimumab-in-ankylosing-spondylitis-assessed-by-matching-adjusted-indirect-comparison-using-pivotal-phase-3-clinical-trial-data/. Accessed 5 June 2022.